核梭杆菌
结直肠癌
癌症研究
转移
上皮-间质转换
大肠癌小鼠模型的建立
梭杆菌
生物
医学
内科学
癌症
拟杆菌
遗传学
细菌
牙龈卟啉单胞菌
牙周炎
作者
Cheng Kong,Xuebing Yan,Yefei Zhu,Huanhuan Zhu,Ying Luo,Peipei Li,Sylvain Ferrandon,Matthew F. Kalady,Renyuan Gao,Jide He,Fang Yin,Xiao Qu,Jiayi Zheng,Yaohui Gao,Qing Wei,Yanlei Ma,Junyan Liu,Huanlong Qin
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-06-23
卷期号:81 (17): 4485-4498
被引量:81
标识
DOI:10.1158/0008-5472.can-21-0453
摘要
Emerging research has revealed regulation of colorectal cancer metabolism by bacteria. Fusobacterium nucleatum (Fn) plays a crucial role in the development of colorectal cancer, however, whether Fn infection modifies metabolism in patients with colorectal cancer remains unknown. Here, LC-MS/MS-based lipidomics identified the upregulation of cytochrome P450 monooxygenases, primarily CYP2J2, and their mediated product 12,13-EpOME in patients with colorectal cancer tumors and mouse models, which increased the invasive and migratory ability of colorectal cancer cells in vivo and in vitro by regulating the epithelial-mesenchymal transition (EMT). Metagenomic sequencing indicated a positive correlation between increased levels of fecal Fn and serum 12,13-EpOME in patients with colorectal cancer. High levels of CYP2J2 in tumor tissues also correlated with high Fn levels and worse overall survival in patients with stage III/IV colorectal cancer. Moreover, Fn was found to activate TLR4/AKT signaling, downregulating Keap1 and increasing NRF2 to promote transcription of CYP2J2. Collectively, these data identify that Fn promotes EMT and metastasis in colorectal cancer by activating a TLR4/Keap1/NRF2 axis to increase CYP2J2 and 12,13-EpOME, which could serve as clinical biomarkers and therapeutic targets for Fn-infected patients with colorectal cancer. SIGNIFICANCE: This study uncovers a mechanism by which Fusobacterium nucleatum regulates colorectal cancer metabolism to drive metastasis, suggesting the potential biomarker and therapeutic utility of the CYP2J2/12,13-EpOME axis in Fn-infected patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI